Arch Oncology Overview
- Founded
- 2006
- Status
- Private
- Employees
- 32
- Latest Deal Type
- Series C
- Latest Deal Amount
- $105M
- Investors
- 18
Arch Oncology General Information
Description
Developer of second-generation anti-CD47 antibodies designed to offer treatment for solid tumors. The company's antibodies represent a new class of checkpoint inhibitors that bridge the innate and adaptive immune systems to attack cancer and it not only acts as an immune checkpoint inhibitor but also selectively kills tumor cells, helping patients with required treatment options to treat cancer.
Contact Information
Website
www.archoncology.com
Formerly Known As
Vasculox, Tioma Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 2000 Sierra Point Parkway
- Suite 700
- Brisbane, CA 94005
- United States
+1 (415) 000-0000
Arch Oncology Timeline
Arch Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC (Series C) | 27-Apr-2021 | $105M | 00000 | 00000 | Completed | Generating Revenue |
| 10. Later Stage VC (Series B) | 11-Mar-2021 | 0000 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 9. Debt - PPP | 29-Apr-2020 | 00000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 8. Later Stage VC (Series B) | 25-Mar-2019 | 0000 | 000.00 | 0000 | Completed | Clinical Trials - Phase 1 |
| 7. Later Stage VC (Series A1) | 04-Feb-2018 | 00.00 | 000.00 | 000 | Completed | Pre-Clinical Trials |
| 6. Later Stage VC (Series A) | 04-Aug-2016 | 000.00 | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
| 5. Grant | 29-Sep-2013 | 00000 | Completed | Pre-Clinical Trials | ||
| 4. Grant | 01-May-2013 | 00000 | Completed | Pre-Clinical Trials | ||
| 3. Grant | 01-May-2012 | $707K | Completed | Pre-Clinical Trials | ||
| 2. Grant | 01-Aug-2011 | $276K | Completed | Generating Revenue |
Arch Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00.0 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 00,000,000 | 00.000000 | 00.0 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A1 | 15,393,186 | $0.001000 | $0.06 | $0.69 | $0.69 | 1x | $0.69 | 8.22% |
Arch Oncology Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of second-generation anti-CD47 antibodies designed to offer treatment for solid tumors. The company's antibodi
Drug Discovery
Brisbane, CA
32
As of 2021
00000
0000
0000-00-00
00000000000
00000
00000000
te irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Exce
0000 000000000
San Carlos, CA
00
As of 0000
00000
0000
0000-00-00
00000000000
00000
00000000
met, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000 000000000
Haddonfield, NJ
0
As of 0000
000.00
00.00
0000-00-00
00000000000
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialArch Oncology Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Apexigen | Venture Capital-Backed | San Carlos, CA | 00 | 00000 | 00000000000 | 00000 |
| 00000000 000000000 | Venture Capital-Backed | Haddonfield, NJ | 0 | 000.00 | 00000000000 | 000.00 |
Arch Oncology Patents
Arch Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200297842-A1 | Therapeutic sirp-alpha antibodies | Pending | 14-Nov-2018 | 00000000000 | |
| EP-3880239-A1 | Therapeutic sirpalpha antibodies | Pending | 14-Nov-2018 | 00000000000 | |
| CA-3119748-A1 | Therapeutic sirp.alpha. antibodies | Pending | 14-Nov-2018 | 00000000000 | |
| AU-2019380503-A1 | Therapeutic sirpα antibodies | Pending | 14-Nov-2018 | 00000000000 | |
| EP-3836960-A1 | Therapeutic cd47 antibodies | Pending | 13-Aug-2018 | C07K16/2803 |
Arch Oncology Executive Team (24)
Arch Oncology Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carole Nuechterlein JD | Roche Venture Fund | Board Member | 000 0000 |
| Drew Dennison | Lightchain Capital | Board Member | 000 0000 |
| Eric Pham Ph.D | Cowen Healthcare Investments | Board Member | 000 0000 |
| Joe Biller | 3x5 Partners | Board Member | 000 0000 |
| John Mckearn Ph.D | RiverVest Venture Partners | Chairman | 000 0000 |
Arch Oncology Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialArch Oncology Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Avego Management | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| Broadfin Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Cowen Healthcare Investments | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Eventide Asset Management | Asset Manager | Minority | 000 0000 | 000000 0 |